

Fig. 6: New Drug Approvals 2012*

Brand	Company	Indication	Approval
Voraxaze	BTG International	Methotrexate toxicity	Jan. 17
Picato	Leo Pharma	Actinic keratosis	Jan. 23
Inlyta	Pfizer	Renal cancer	Jan. 27
Erivedge	Genentech	B-cell carcinoma	Jan. 30
Kalydeco	Vertex	Cystic fibrosis	Jan. 31
Zioptan	Merck	Glaucoma	Feb. 10
Surfaxin	Discovery Labs	Resp. distress synd.	Mar. 6
Omontys	Affymax	Anemia	Mar. 27
Amyvid	Avid Radiopharma	Alzheimer's diagnosis	Apr. 6
Stendra	Vivus	Erectile dysfunction	Apr. 27
Elelyso	Pfizer	Gaucher's disease	May. 1
Perjeta	Genentech	Breast cancer	Jun. 8
Belviq	Eisai	Obesity	Jun. 27
Myrbetriq	Astellas	Overactive bladder	Jun. 28
Prepopik	Ferring	Colon cleansing	Jul. 16
Kyprolis	Onyx	Multiple myeloma	Jul. 20
Tudorza Pressair	Forest	COPD	Jul. 23
Zaltrap	Sanofi	Colorectal cancer	Aug. 3
Stribild	Gilead	HIV-1 infection	Aug. 27
Neutroval	Sicor Biotech	Neutropenia	Aug. 29
Linzess	Forest	IBS	Aug. 30
Xtandi	Astellas	Prostate cancer	Aug. 31
Bosulif	Pfizer	Leukemia	Sep. 4
Aubagio	Sanofi	Multiple sclerosis	Sep. 12
Choline C-11	MCPRF	Prostate canc. diagn.	Sep. 12
Stivarga	Bayer	Colorectal cancer	Sep. 27
Jetrea	Thrombogenics	SVA	Oct. 17
Fycompa	Eisai	Seizures	Oct. 22
Synribo	Ivax	Leukemia	Oct. 26
Xeljanz	Pfizer	Rheumatoid arthritis	Nov. 6
Cometriq	Exelixis	Thyroid cancer	Nov. 29
Iclusig	Ariad	Leukemia	Dec. 14
Signifor	Novartis	Cushing's disease	Dec. 14
Raxibacumab	HGS	Anthrax	Dec. 14
Gattex	NPS	Short bowel syndrome	Dec. 21
Juxtapid	Aegerion	HoFH	Dec. 21
Eliquis	Bristol-Myers Squibb	SPAF	Dec. 28
Sirturo	Janssen	Tuberculosis	Dec. 28
Fulyzaq	Salix	HIV-assoc. diarrhea	Dec. 31

* NMEs and new biologics approved by FDA's Center for Drug Evaluation and Research (CDER)